Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    13-February-2001      
Issue 44 Next Update - 14:00 UTC 08:00 EST    14-February-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Generic Forms Of Daypro ® And Ritalin ® Approved By FDA

Drugs Treat Arthritis And ADHD

Watson Pharmaceuticals, Inc. announced today that the Food and Drug Administration (FDA) has approved two of Watson's abbreviated new drug applications: Oxaprozin Tablets, 600 mg and Methylphenidate Hydrochloride Extended Releases Tablets USP, 20 mg.

Oxaprozin Tablets are the generic equivalent to G. D. Searle and Co.'s Daypro(R) Tablets, 600 mg, which are indicated for the acute and long-term use in the management of the signs and symptoms of osteoarthritis and rheumatoid arthritis. Watson plans to manufacture this product at its Corona, California facility.

Methylphenidate Hydrochloride Extended Release Tablets are the generic equivalent to Novartis Pharmaceuticals' Ritalin-SR(R) Tablets, 20 mg, which are indicated as an integral part of a total treatment program for stabilizing effects in children with a behavioral syndrome characterized by developmentally inappropriate symptoms, such as moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Watson plans to manufacture this product at its Carmel, New York facility.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.